Immunocore presents promising data on HIV functional cure candidate at CROI 2025

From GlobeNewswire: 2025-03-10 15:00:00

Immunocore presented initial multiple ascending dose data for HIV functional cure candidate IMC-M113V at CROI 2025. The drug was well tolerated with signals of dose-dependent reduction in active reservoir and viral control after ART interruption. Enrollment in the trial continues with higher doses being evaluated. The data showed a trend of reduction in intact HIV DNA, delayed viral rebound, and viremia control in some participants. IMC-M113V uses a T cell receptor to target HIV-infected cells and aims for sustained control of HIV without lifelong ART. Immunocore is advancing clinical candidates for HIV and HBV functional cure.



Read more at GlobeNewswire: Immunocore presents initial multiple ascending dose data